Incyte drops HIV drug
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Incyte is discontinuing development of its HIV candidate dexelvucitabine (DFC, formerly Reverset) due to "a recently observed increase in the frequency of grade 4 hyperlipasemia" in the firm's long-term extension of a Phase IIb trial, the firm says April 3. "Based on these observations, Incyte believes it is in the best interests of patients to discontinue development of DFC and has decided to stop enrollment of [a] recently initiated Phase IIb trial," the firm says. Incyte previously had cited hyperlipasemia, or pancreatic inflammation, as one of FDA's reasons for not giving a green light for the firm's Phase III program (1Pharmaceutical Approvals Monthly October 2005, p. 6). Incyte notes that "even though lower doses [of DFC] could be safer, those we've studied have not been effective," further reinforcing the decision to discontinue the nucleoside analog reverse transcriptase inhibitor...
You may also be interested in...
Incyte Reverset Program Delayed 12-18 Months For Confirmatory Study
FDA's refusal to green-light Phase III study plans for Incyte's Reverset HIV therapy could delay market launch by at least a year, according to the company
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.